Saturday, 22 January 2022

Welcome in NeoVanc

NeoVanc project aims at adapting an off-patent medicine to the specific need of paediatric populations: in specific to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age in order to be able to register it for use in this age group with a PUMA. 


This project has been funded with the support of the European Commission under the FP7 programme.

Login:

Reserved Access to the our services for our Partners.

Latest:

27/11/2021 - News & Events

New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis

PRESS RELEASE

NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the…
Read more
12/11/2020 - News & Events

Dr Louise Hill presents sub-study findings at ESPID 2020

Candida and Vancomycin Resistant Enterococcus Colonisation in Septic Neonates on Vancomycin…
Read more
07/09/2020 - News & Events

NeoVanc trial in the final stretch towards completion!

The second trial in neonatal sepsis sponsored by Penta is now in its final stretch towards…
Read more

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Call: FP7-HEALTH-2013-INNOVATION-1
Privacy policy | Terms and conditions

E-mail: info@penta-id.org